This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT04648969 |
|---|---|
| Status | Completed |
| Phase | Phase 2 |
| Sponsor | Stephanie B. Seminara, MD |
| Enrollment | 18 participants |
| Design | Interventional, Na, Single Group, Masking: None |
| Conditions | Hypogonadotropic Hypogonadism |
| Interventions | kisspeptin 112-121; GnRH |
| Start | May 3, 2019 |
| Primary completion | Aug 31, 2025 |
| Study completion | Aug 31, 2025 |
| Results posted | Yes, in the registry |
| Registry last updated | Aug 26, 2026 |
Compounds on this site that cite this trial
What the registry says the trial is about
The goal of this study is to develop novel treatments for patients with a condition called hypogonadotropic hypogonadism (HH) through the use of exogenous kisspeptin.
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| Average Change in Luteinizing Hormone (LH) Pulse Amplitude in Response to Kisspeptin | 52 hours |
1 secondary outcome also registered. See the registry record for the full list.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Nov 3, 2026. See the trial changes feed for what has changed recently.
More trials of Kisspeptin-10
- Kisspeptin-10 and Leuprolide acetate: Phase 2 Trial (NCT05896293)
- TAK-448: Phase 2 Trial (NCT02369796)
- Kisspeptin-10: Phase 1 Trial (NCT05633966)
- Kisspeptin-10 and GnRH: Phase 1 Trial (NCT01438073)
Research area: Sexual health and melanocortin. Every registered trial we follow is in the clinical trial tracker, and the labels used on this page are explained in our evidence standards.
